Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
27 Apr 2020
Long-term use of brivaracetam as an adjunctive treatment is well tolerated and effective in patients with focal seizures or primary generalized seizures, as shown in a study.
01 Apr 2019
Perampanel is safe and effective for treating refractory focal seizures in both Asian and non‐Asian populations, a study has found.
Elvira Manzano, 20 Jun 2018
A higher proportion of patients with systemic lupus erythematosus (SLE) experienced improvements in joint and skin symptoms with baricitinib 4 mg once daily vs placebo in a phase II randomized, double-blind, global study.

Ceritinib ups hyperglycaemia risk

14 Nov 2019
One million deaths in China occur each year as a result of diabetic complications.

Ceritinib use appears to carry a significant risk of developing hyperglycaemia, a new Japan study has found.

Accessing the Japan Adverse Drug Even Report (JADER) database, researchers identified signals of hyperglycaemia and related events. They identified 7,837 such cases out of 887,636 adverse drug reactions reported in the databases. Reported odds ratios (ROR) were calculated using a two-by-two contingency table.

Of the three anaplastic lymphoma kinase inhibitors (ALKIs), only ceritinib resulted in significant RORs. There were 429 database entries that initiated ceritinib use before September 2017; four of them developed hyperglycaemia, indicating an insignificant risk (ROR, 1.06, 95 percent confidence intervals [CI], 0.39–2.83).

On the other hand, seven of 132 patients who started ceritinib medication after September 2017 showed hyperglycaemia and related events. The resulting risk estimate was significant (ROR, 6.29, 95 percent CI, 2.94–13.5).

“The insignificant ROR before September 2017 might be biased due to the limited case application and/or possible prior use of crizotinib or alectinib,” researchers explained.

A similar pattern of effect was reported when JADER datapoints with use of antidiabetes agents were excluded. Of the 545 remaining users of ceritinib, eight developed hyperglycaemia events (ROR, 2.54, 95 percent CI, 1.27–5.12).

In any of the analyses performed above, crizotinib and alectinib, both ALKIs, did not result in a significantly higher likelihood of developing hyperglycaemia.

“Clinicians including diabetologists and oncologists should emphasize vigilance for ceritinib-associated hyperglycaemia,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
27 Apr 2020
Long-term use of brivaracetam as an adjunctive treatment is well tolerated and effective in patients with focal seizures or primary generalized seizures, as shown in a study.
01 Apr 2019
Perampanel is safe and effective for treating refractory focal seizures in both Asian and non‐Asian populations, a study has found.
Elvira Manzano, 20 Jun 2018
A higher proportion of patients with systemic lupus erythematosus (SLE) experienced improvements in joint and skin symptoms with baricitinib 4 mg once daily vs placebo in a phase II randomized, double-blind, global study.